1 terminated. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Terminated 1 |
Follow IDM 2101: new trials by email Literature Review of IDM 2101 trials Research Report on IDM 2101
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure OSE2101, Docetaxel, Pemetrexed - Non Small Cell Lung Cancer | Phase 3 | Terminated | OSE Immunotherapeutics | 219 | 2016-02-12 | 2024-02-02 |
Carcinoma, Non-Small-Cell Lung (1)
Czechia (1) · France (1) · Germany (1) · Hungary (1) · Israel (1) · Italy (1) · Poland (1) · Spain (1) · United Kingdom (1) · United States (1)
2015 (1)